|Year : 2021 | Volume
| Issue : 2 | Page : 178-189
Pregnancy with paroxysmal nocturnal hemoglobinuria: A case series with review of the literature
Yara Mohammad Al-Dosari1, Hazza Al-Zahrani2, Fahad Al-Mohareb3, Shahrukh Hashmi4
1 Internal Medicine Department, Bahrain Defence Force Hospital and Royal Medical Services; King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
2 Adult Hematology/Bone Marrow Transplantation Section, Oncology Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
3 Adult Hematology, HSCT Section, Oncology Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
4 Adult Hematology/Bone Marrow Transplantation Section, Oncology Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia; Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
|Date of Submission||20-Jun-2020|
|Date of Decision||31-Dec-2020|
|Date of Acceptance||15-Apr-2021|
|Date of Web Publication||29-Apr-2021|
Yara Mohammad Al-Dosari
King Faisal Specialist Hospital and Research Center, PO Box 3354, Riyadh 11211
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired hematopoietic stem cell disorder, and eculizumab and ravulizumab are its two approved therapies. Only few case series/reports have reported the outcomes of pregnancies in patients with PNH despite the increased risk of thrombosis. Similarly, there is limited knowledge regarding the effect of the approved treatments on conception and pregnancy outcomes. Here, we report the first series of pregnancies in PNH patients from the Middle Eastern region from our tertiary care hospital. Ten pregnancies in four females after diagnosis with PNH were identified. In terms of PNH management, only eculizumab was used, as the safety of ravulizumab use in pregnancies has not yet been established. In the antepartum period, the patients had variable symptoms that ranged from mild symptoms including epistaxis, tea-colored urine and vaginal bleeding to life-threatening vessel thrombosis. Further, red blood cell and platelet transfusions were required because of bleeding and hemolysis in four pregnancies. The pregnancy outcomes varied, but based on these, the safety of eculizumab use during pregnancy remained inconclusive. The postpartum period was complicated in one case by portal vein thrombosis and was managed accordingly. In conclusion, pregnant females with PNH are at an increased risk for complications due to PNH, and thus experienced hematologists and obstetricians should be involved jointly in their care.
Keywords: Complications, paroxysmal nocturnal hemoglobinuria, pregnancy
|How to cite this article:|
Al-Dosari YM, Al-Zahrani H, Al-Mohareb F, Hashmi S. Pregnancy with paroxysmal nocturnal hemoglobinuria: A case series with review of the literature. Saudi J Med Med Sci 2021;9:178-89
|How to cite this URL:|
Al-Dosari YM, Al-Zahrani H, Al-Mohareb F, Hashmi S. Pregnancy with paroxysmal nocturnal hemoglobinuria: A case series with review of the literature. Saudi J Med Med Sci [serial online] 2021 [cited 2021 Sep 18];9:178-89. Available from: https://www.sjmms.net/text.asp?2021/9/2/178/315135
| Introduction|| |
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired clonal hematopoietic stem cell disorder caused by somatic mutation in phosphatidylinositol glycan class A gene (PIGA gene), resulting in deficiency or absence of glycosylphosphatidylinositol (GPI)-anchored proteins.
Clinical manifestation of PNH is characterized by intravascular hemolysis, bone marrow failure (BMF) and thrombosis. It can also mimic other hematological disorders such as aplastic anemia (AA) and myelodysplastic diseases (MDS), although PNH can have a combination of both AA and MDS., According to Brando et al., classical signs and symptoms of PNH include hemoglobinuria or hemosiderinuria, unexplained direct antiglobulin tests, negative hemolysis, aplastic anemia, thrombosis at unusual sites and dystonic symptoms (abdominal pain or dysphagia). For confirmatory diagnosis, flow cytometry is used, as it can demonstrate the absence or deficiency in the expression of GPI-anchored protein in a sizable portion of peripheral blood, mainly in red blood cells (RBC), neutrophils and monocytes, called as 'PNH clones,' which are fundamentals in diagnosing PNH.,,,
Pregnancy is a challenging period due to the physiological changes,,,, and requires specific attention during interventions of chronic diseases, especially in hematological disorders. Further, pregnancy in patients with PNH increases maternal and fetal mortality and morbidity as a result of an exacerbation of intravascular hemolysis, thrombosis and bone marrow failure., In the management of PNH, eculizumab therapy has both been shown to be safe and effective as well as reported to potentially have teratogenic effects that may require dosage and frequency adjustments; the effect of ravulizumab on pregnancy outcomes has yet to be reported.,,,,
Currently, there is no report from Saudi Arabia or the Middle East regarding the prevalence and incidence of pregnancy in PNH, in addition to limited data in general regarding PNH in pregnancy and the management approaches in such a high-risk group [Table 1].,, Therefore, this case series would add to existing literature.
|Table 1: List of case series/case reports on pregnancy with paroxysmal nocturnal hemoglobinuria in the literature|
Click here to view
| Description of Cases|| |
For this case series, the data of all patients with PNH who presented to our Hematology, Stem Cell Transplantation & Cellular Therapy center between 2013 and 2021 were retrospectively analyzed. The study was approved by the Research Advisory Council (RAC)/Ethics Committee at King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia.
During the period, a total of 20 patients with PNH had been treated at our center. Of these eight were females: two were not within the reproductive age, two died following hematopoietic stem cell transplant complications, and the remaining four had 10 pregnancies after the diagnoses of PNH.
The diagnosis was initially based on clinical presentations, and then following the minimal essential criteria for PNH diagnosis including: (1) flow cytometry analysis of peripheral blood erythrocytes, granulocytes or both (PNH clone), (2) complete blood count (CBC), reticulocytes count, serum concentration of lactic dehydrogenase (LDH), bilirubin and haptoglobin, and (3) bone marrow biopsy for those with concomitant underlining bone marrow disease. The eculizumab therapy protocol was as stated in the literature:,, initially a dose of 600 mg IV weekly for the first 4 weeks, followed by 900 mg IV for 1 week and then 900 mg every 2 weeks. Doses were modified or reduced based on the patient's tolerance to the regular dosing, in the presence of side effects, and per the availability of the medication in the pharmacy, given its cost.
Below is the summary of each patient's clinical course details regarding clinical features, relevant laboratory findings (e.g. hemograms, PNH clone, bilirubin and LDH), treatments, and the outcome are summarized in [Table 2] and [Table 3].
|Table 2: Summary of cases and pregnancy outcomes with the use of eculizumab and anticoagulation therapy (the median values are stated for laboratory results)|
Click here to view
|Table 3: Summary of cases and pregnancy outcomes with the use of eculizumab, anticoagulation therapy and documented complications (ante, intra, postpartum period)|
Click here to view
A 43-year-old female diagnosed with PNH in 2013 (aged 38 years) manifesting with mild cytopenia and PNH clone of 63% on WBC–monocytes, was treated with 900 mg of eculizumab every 2 weeks (standard dose) and remained in a stable condition. In 2015, she became pregnant with a singleton; eculizumab was continued throughout the antepartum period, and the dose was increased to 1200 mg because of worsening clinical situation, especially anemia. In addition to prophylactic low-molecular-weight heparin (LMWH) (dose of 20 mg subcutaneous daily), ferrous sulfate and folic acid were also prescribed. At 33 weeks of gestation, the pregnancy was complicated with polyharmonies (amniotic fluid index, >24 cm) and large fetus for gestational age that required hospitalization for observation and monitoring.
At 38 weeks of gestation, after the failure of induction of labor, a caesarian section was performed. In addition, RBC and platelet transfusions were given intrapartum. The product was a full-term infant with a birth weight of 4000 grams (larger than the average childbirth weight in Saudi Arabia) with an Apgar score of 9, who was admitted in the neonatal intensive care unit (NICU) with a stable course. The infant had dysmorphic features, macrocephaly, hypotonia, right undescended testes and Hirschsprung disease, which is most likely because the family had a strong history of multiple congenital anomalies. In the immediate postpartum period, the patient complained of acute abdominal pain, and ultrasound (US) doppler confirmed portal and superior mesenteric vein thrombosis, following which dose of LMWH was increase to 40 mg subcutaneous daily and dose was adjusted according to the platelet count, which ranged at that time between 17 to 33 × 109/L.
The transient thrombocytopenia required platelet transfusion and the patient stabilized without any complications and was maintained on subhepatic LMWH. Six weeks post-delivery, she was shifted to rivaroxaban for long-term anticoagulation. On the last follow up in October 2020, she continued to have no acute events on maintenance eculizumab (900 mg) every 2 weeks and rivaroxaban.
A 31-year-old lady was diagnosed with PNH in 2015 (aged 25 years). The patient had a history of bone marrow failure, received antithymocyte globulin therapy followed by cyclosporine and achieved complete remission. Five years later, patient presented with iron deficiency symptoms and hemolysis manifesting as tea-colored urine with rise of PNH clone size to WBC was 48.2%. She had not been on eculizumab therapy; the reason for the same was not clearly stated in our registry but could be because the patient had a stable disease course.
In 2017, she became pregnant, and was treated with 40 mg of enoxaparin for high risk of thrombosis. The antepartum period was stable with no complication, except for mild epistaxis. Fetal US was normal with no intrauterine growth restriction (IUGR). Spontaneous vaginal delivery occurred at 39 weeks of gestation after induction of labor with no complications. The product infant was stable, birth weight of 3020 g, Apgar score was 9, with no NICU admissions. Postpartum period was uncomplicated and LMWH prophylaxis (40 mg) was given for 6 weeks post-delivery.
The patient was followed-up every 3 months at the hematology clinic for assessment of disease control and iron replacement compliance, as needed (for any drop in hemoglobin). The assessment was based on clinical symptoms and laboratory parameters including hemoglobin, LDH, bilirubin, haptoglobin, reticulocytes and renal function to observe any signs of hemolysis.
The patient had her second pregnancy in 2018, following which folic acid and prophylactic LMWH was started. During her follow up, she developed tea-colored urine and epistaxis at 27 weeks of gestation. Thus, signs of hemolysis were confirmed with hemoglobin: 114 g/L, reticulocyte auto 86.8 109/L, haptoglobin <0.1/L and LDH 596 U/L. The prophylactic dose of LMWH was maintained on 40 mg and she was advised for good hydration. Fetal US showed normal interval growth with no IUGR and normal blood flow.
Emergency C-section at 39 weeks of gestation was performed due to hyperstimulation and fetal distress with no complications. The product infant was stable with a birth weight of 3000-gram, Apgar score of 9 and with no NICU admission. The postpartum period was uneventful and LMWH prophylaxis was initiated post-delivery and continued for 6 weeks.
The patient had her third pregnancy in November 2020 and was started on prophylactic LMWH of 40 mg. During the regular follow up, she complained of mild discomfort in the left leg (calf region), and accordingly deep vein thrombosis ruled out by US doppler. In her 8th week of gestation, the patient complained of lower abdominal pain and vaginal bleeding. A transvaginal US confirmed non-viable pregnancy and missed abortion, and thus she underwent emergency evacuation and curettage. Laboratory parameters was reassuring and did not show any signs of hemolysis. Postpartum period was uneventful, and she was discharged in a stable condition after 2 days and with advice to continue on prophylactic LMWH until her next follow up.
A 39-year-old female was diagnosed with PNH in 2013 (aged 32 years), manifesting with fatigability, skin thrombophlebitis and PNH on WBC clone size was 80.6%. The patient refused treatment with eculizumab at that time. However, she had a history of severe aplastic anemia for couple of years controlled on cyclosporine and aspirin (81 mg) because of worsening of her cytopenia. She had a history of four abortions, three intrauterine fetal deaths (IUFD) and one stillbirth due to brain atrophy.
In 2017, the patient became pregnant, and enoxaparin 40 mg and folic acid supplement were added to aspirin; however, cyclosporine was discontinued to avoid its teratogenicity. The antepartum period was complicated with bone marrow suppression, mild vaginal bleeding, frequent hemolysis and dropping of platelets level, and thus she required frequent RBC and platelet transfusion, glucocorticoid and intravenous immunoglobulin therapy. At 31-week of gestation, 600 mg eculizumab was started as she presented with low platelets and low hemoglobin. Enoxaparin was switched to prophylactic fondaparinux (2.5 mg) because the patient developed heparin-induced thrombocytopenia (HIT). However, fetal US showed normal interval growth and normal blood flow.
Preterm rupture of membranes occurred at 36 weeks of gestation, then induction of labor started and eventually progressed with spontaneous vaginal delivery. The infant was full term and stable, weighted 2320 grams, the Apgar score was 9, and had no complications that required NICU admissions. Postpartum period was completed with no complications and she was continued on eculizumab and fondaparinux for 6 weeks.
During regular follow ups, the patient had a missed abortion in January 2019 despite being on eculizumab. The details are not known, as the diagnosis was in a local hospital; however, laboratory parameters were within normal range and no hemolysis or drop in hemoglobin was detected.
In the last follow up at the time of reporting this case, patient was pregnant and advised to continue with eculizumab (600 mg every 4 weeks), but fondaparinux was not started, as the patient was in her first trimester. In addition, an expert obstetrician was consulted for following the patient.
A 38-year-old female diagnosed with PNH in 2014 (aged 32 years) manifested with back pain, pancytopenia, hepatitis B infection (on Tenofovir therapy), PNH clone size on WBC of 78.3%, and bone marrow biopsy showing hypocellularity but no features of myelodysplasia. Initially, the patient remained on cyclosporine 100 mg and planned for stem cell transplantation, but patient refused treatment.
In 2016, the patient agreed for treatment and was started on eculizumab 900 mg. She had frequent RBC and platelet transfusions. In 2017, she became pregnant with a singleton; however, the gestation did not progress. The pregnancy was complicated by IUFD at 25 weeks of gestation, despite treatment with eculizumab, enoxaparin and folic acid. Platelet transfusion was given during the termination of pregnancy. The postpartum period was uncomplicated and LMWH was continued postpartum for 3 weeks
In 2018, while on treatment with 900 mg eculizumab, the patient again became pregnant. At 28 weeks of gestation, she presented to the emergency department (ED) with vaginal bleeding and abdominal pain, and after a few hours, she delivered dead fetus and placenta spontaneously. The patient was admitted for 1 day for monitoring, and then discharged on 40 mg prophylactic enoxaparin for 6 weeks.
On November 2020, during the telephonic follow up due to the COVID-19 pandemic, the patient reported that she became pregnant, but the pregnancy terminated spontaneously while on eculizumab therapy. In the last follow up in hematology clinic in January 2021, patient was in a stable condition clinically and laboratory, and advised to continue eculizumab regimen.
| Discussion|| |
PNH often occurs in females during the reproductive age. Conception is discouraged in patients with PNH because of increased risk of thrombosis. The high possibility of thrombosis is likely related to pregnancy physiological changes such as increase in complement activity and hypercoagulability state and also with the pathophysiology of PNH that might augment the risk of emergency delivery.,,, Thrombosis is associated with serious complications for the mother and the fetus, and thus obstetrician experts are involved in care of pregnant patients with PNH.,
In this case series, we present the course of 10 pregnancies in four patients after PNH diagnosis and add to the limited data available in the literature.,, To the best of the authors knowledge, only 62 cases have been published in 20 articles discussing pregnancy with PNH, with the current paper being one of few series and the first from the Middle East region [Table 1] and [Table 4].
|Table 4: Review of literature for pregnancy with paroxysmal nocturnal hemoglobinuria|
Click here to view
Clinical presentation of our patients varied from mild symptoms such as back pain and thrombophlebitis to severe potential symptoms such as bone marrow failure and life-threatening vessel thrombosis. However, three of the four patients had complete hypoplastic bone marrow features and hemolysis [Table 2] and [Table 3]. Antepartum maternal complications included thrombocytopenia and hemolysis manifesting as epistaxis and dark urine, in addition to poor significant outcome such as termination of pregnancy because of IUFD or spontaneous abortion. During the antepartum period, platelet and RBC transfusions were on demand for all our patients when platelets counts were >20 or <50 or hemoglobin was <80 mg/L and at the time of delivery. During the delivery phase, three cases were planned for induction of labor for spontaneous vaginal delivery, and three cases had spontaneous abortion. In addition, two cases underwent cesarean section delivery due to failed induction of labor and fetal distress and one case had a missed abortion and underwent emergency evacuation and curettage. According to the existing literature and our case series, the mode of delivery (i.e., cesarean sections and spontaneous) were almost equal, suggesting that PNH might not have a significant impact on the mode of delivery.
The postpartum period was controlled clinically and with follow up parameters for hemolysis (CBC, LDH, haptoglobin, reticulocytes and bilirubin) and thrombosis complications. All patients were maintained on prophylactic LMWH for 6 weeks after delivery. The postpartum period was uncomplicated in three cases except for Case 1, wherein portal vein thrombosis was reported and managed conservatively with no further complications.
Fetal outcomes for our patients were significant for two cases. In Case 1, the infant was large for the gestational age, with congenital anomaly, and was admitted to the NICU. In Case 4, the patient had IUFD and four abortions. Interestingly, Case 2, who was not on eculizumab, delivered a healthy fetus, whereas the other three patients who were on eculizumab had the above-mentioned fetal complications. From the literature, 86% of the newborns have been found to be healthy, 6% had fetal deaths, and in 8%, the outcomes were not stated with variable usage of eculizumab. Therefore, eculizumab might have a rule in the relatively safe conclusion discussed in the evidence.
We found that in the literature, the use of anticoagulants during pregnancy varied: 60% used prophylactic heparin, 18% had therapeutic doses of heparin, 16% did not receive any anticoagulants and in 4% its usage was not stated. Therefore, the preferable use of prophylactic or therapeutic strategy in pregnancy with PNH could not be determined. It should be noted that unless contraindicated, prophylactic LMWH is prescribed to pregnant women during the third trimester and continued for 6–12 weeks postpartum, as the risk of thrombosis is high., Many studies recommend it when the clone size is >50%. In our cases, all our patients received anticoagulants (enoxaparin/fondaparinux) during both antepartum and postpartum periods.
According to Parker et al., thrombophilia is the leading cause of mortality in PNH, with thromboembolic events being directly related to the PNH clone size. The study by Hall et al. supports this hypothesis, as they found that in patients with PNH clone >50% GPI-AP–deficient granulocytes, the 10-year risk of thrombosis in PNH patient was 44% and it was 5.8% in patients with <50% GPI-AP–deficient granulocyte. In another study, it was shown that compared with patients with PNH clone of 20%, those with >70% GPI-AP–deficient granulocytes had an 11.8-fold increased risk of thrombosis. Therefore, observing clone size can assist in the management plan, in addition to the hypercoagulable state of pregnancy, which tremendously increases the risk of thrombosis.
The efficacy of anticoagulants in pregnancy with PNH have been supported strongly by Morita et al. and Patel et al. whereas de Guibert et al. reported some cases with thrombosis even after the use of anticoagulants. Therefore, there is need for further studies that provide stronger evidence for use of antithrombotic medications in pregnancy with PNH.
Eculizumab and ravulizumab are the approved medication for management of PNH. There is contrasting evidence regarding the safety of eculizumab use in pregnancy, as it has been reported to not cross the cord blood/placental barrier or be excreted in the breast milk, but it has also been reported that some proportion does cross cord blood/placental barrier. In the study by Kelly et al., eculizumab was detected in low levels in 7 of 20 cord blood samples. Eculizumab was also found in the placental blood of two patients with PNH after delivery, but with normal complement activity. Therefore, evidence suggests that in cases of suggests that if eculizumab does cross the placenta, the levels are very low to activate the complement system and cause any adverse effects to the fetus. In PNH generally, a multinational longitudinal study found that eculizumab effectively stops intravascular hemolysis, thereby reducing risk of thrombosis and improving the quality of life. However, specifically during pregnancy, its safety remains unclear as reported by Rodríguez-Ferreras and Velasco-Roces that the Drug's Technical Data Sheet and studies have warned regarding its potential teratogenic risk and discourage its use. This contrasts with the observations of other case series and recent reviews about its safety during pregnancy.,,,,,,
In the cases reported by Guibert et al. (which account for 52% of all reported cases in the literature), eculizumab was not prescribed during either antepartum or postpartum periods. Overall, its use varied [Table 4], with 22% of all cases receiving it during the entire pregnancy, 18% in different trimesters and 8% did not receive it. During postpartum, 30% of the reported cases received eculizumab, and 14% did not. However, in our cases, three patients received eculizumab during antepartum and postpartum, but Case 2 did not and the reason for not initiating this therapy was not documented. In Case 3, the patient initially refused the therapy, but it was initiated at 31 weeks of gestation and postpartum; notably, both cases remained stable. The eculizumab dosage and frequency usually increased during pregnancy due to the physiological and pathophysiological factors of pregnancy and PNH, respectively, an approach supported by the existing literature.
Overall, the findings in our cases and existing literature outcomes are similar. Management of pregnancy with PNH is based on observational data and preexisting published experience; therefore, there is need for an established protocol to standardize management plans for such a high-risk group.
| Conclusion|| |
Based on our experience from the reported cases, it can be stated that pregnancy is not recommended in patients with PNH due to the high risk of complications, and in cases of pregnancies, both hematological and obstetrician experts should be involved in patient care. All PNH pregnancies should be monitored clinically and through laboratory parameters for any symptoms/signs of hemolysis or thrombosis and to determine use prophylactic anticoagulants for thrombosis prevention and for use of eculizumab therapy. The safety of eculizumab use during pregnancy remain inconclusive, and thus there is need for prospectively studies with long-term follow-up to determine the effectiveness of eculizumab as well as determine the outcome of pregnancy with PNH.
This case series was approved by the Research Advisory Council /Ethics Committee at King Faisal Specialist Hospital (Ref no.: RAC#2131-049), and adhered to the guidelines of the Declaration of Helsinki, 2013.
This article was peer-reviewed by two independent and anonymous reviewers.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Brodsky RA. Paroxysmal nocturnal hemoglobinuria. Blood 2014;124:2804-11.
Yu F, Du Y, Han B. A comparative analysis of clinical characteristics of patients with paroxysmal nocturnal hemoglobinuria between Asia and Europe/America. Int J Hematol 2016;103:649-54.
Patel SJ, Ajebo G, Kota V, Guddati AK. Analysis of outcomes in hospitalized pregnant patients with acute myeloid leukemia. Am J Blood Res 2020;10:68-75.
Brando B, Gatti A, Preijers F. Flow cytometric diagnosis of paroxysmal nocturnal hemoglobinuria: Pearls and pitfalls – A critical review article. EJIFCC 2019;30:355-70.
Parker C, Omine M, Richards S, Nishimura JI, Bessler M, Ware R, et al
. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood 2005;106:3699-709.
Mercuri A, Farruggia P, Timeus F, Lombardi L, Onofrillo D, Putti MC, et al
. A retrospective study of paroxysmal nocturnal hemoglobinuria in pediatric and adolescent patients. Blood Cells Mol Dis 2017;64:45-50.
Muñoz-Linares C, Ojeda E, Forés R, Pastrana M, Cabero M, Morillo D, et al
. Paroxysmal nocturnal hemoglobinuria: A single Spanish center's experience over the last 40 yr. Eur J Haematol 2014;93:309-19.
Patriquin C, Leber B. Increased eculizumab requirements during pregnancy in a patient with paroxysmal nocturnal hemoglobinuria: Case report and review of the literature. Clin Case Rep 2015;3:88-91.
Kelly RJ, Höchsmann B, Szer J, Kulasekararaj A, de Guibert S, Röth A, et al
. Eculizumab in pregnant patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 2015;373:1032-9.
Singh A, Sikka P, Suri V, Agrawal N, Chopra S, Kumar B. Pregnancy in a patient with paroxysmal nocturnal hemoglobinuria. Int J Reprod Contracept Obstet Gynecol 2014;3:285-7.
Lauritsch-Hernandez LS, Kraehenmann F, Balabanov S, Kimmich N. Eculizumab application during pregnancy in a patient with paroxysmal nocturnal hemoglobinuria: A case report with review of the literature. Clin Case Rep 2018;6:1582-7.
Sharma R, Keyzner A, Liu J, Bradley T, Allen SL. Successful pregnancy outcome in paroxysmal nocturnal hemoglobinuria (PNH) following escalated eculizumab dosing to control breakthrough hemolysis. Leuk Res Rep 2015;4:36-8.
Bjørge L, Ernst P, Haram KO. Paroxysmal nocturnal hemoglobinuria in pregnancy. Acta Obstet Gynecol Scand 2003;82:1067-71. 10.
Sahu KK, Dhibar DP, Varma S, Malhotra P. CML with pregnancy: Real challenges in developing nations. Leuk Lymphoma 2017;58:1518-9.
Lee SE, Lee JW. Safety of current treatments for paroxysmal nocturnal hemoglobinuria. Expert Opin Drug Saf 2021;20:171-9.
Bastos JM, Pinheiro PL, Rocha LC, Bicalho EC, Cazeli AB, Marcondes SS, et al
. Therapeutic challenges in pregnant women with paroxysmal nocturnal hemoglobinuria: A case report. Medicine (Baltimore) 2018;97:e12155.
Füreder W, Sperr WR, Heibl S, Zebisch A, Pfeilstöcker M, Stefanzl G, et al
. Prognostic factors and follow-up parameters in patients with paroxysmal nocturnal hemoglobinuria (PNH): Experience of the Austrian PNH network. Ann Hematol 2020;99:2303-13.
Miyasaka N. Pregnancy in paroxysmal nocturnal hemoglobinuria. In: Kanakura K, Konoshita T, Nishmura J, editors. Pregnancy in Paroxysmal Nocturnal Hemoglobinuria. Japan: Springer, Tokyo; 2017. p. 347-58.
de Guibert S, Peffault de Latour R, Varoqueaux N, Labussière H, Rio B, Jaulmes D, et al
. Paroxysmal nocturnal hemoglobinuria and pregnancy before the eculizumab era: The French experience. Haematologica 2011;96:1276-83.
Hall C, Richards S, Hillmen P. Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria (PNH). Blood 2003;102:3587-91.
Alashkar F, Saner FH, Vance C, Schmücker U, Herich-Terhürne D, Dührsen U, Köninger A, Röth A. Pregnancy in classical paroxysmal nocturnal hemoglobinuria and aplastic anemia–paroxysmal nocturnal hemoglobinuria: a high-risk constellation. Front Med. 2020;7:543372.
Miyasaka N, Miura O, Kawaguchi T, Arima N, Morishita E, Usuki K, et al
. Pregnancy outcomes of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab: A Japanese experience and updated review. Int J Hematol 2016;103:703-12.
Rodríguez-Ferreras A, Velasco-Roces L. Eculizumab-related abortion in a woman with paroxysmal nocturnal hemoglobinuria: A case report. J Reprod Infertil 2019;20:252-5.
Danilov AV, Brodsky RA, Craigo S, Smith H, Miller KB. Managing a pregnant patient with paroxysmal nocturnal hemoglobinuria in the era of eculizumab. Leuk Res 2010;34:566-71.
Marasca R, Coluccio V, Santachiara R, Leonardi G, Torelli G, Notaro R, et al
. Pregnancy in PNH: Another eculizumab baby. Br J Haematol 2010;150:707-8.
Ando Y, Kida M, Saika M, Chizuka A, Hangaishi A, Urabe A, et al
. Pregnancy and delivery in a PNH patient treated with eculizumab. Rinsho Ketsueki 2014;55:2288-93.
Patel A, Unnikrishnan A, Murphy M, Egerman R, Wheeler S, Richards A, et al
. Paroxysmal nocturnal hemoglobinuria in pregnancy: A dilemma in treatment and thromboprophylaxis. Case Rep Hematol 2017;2017:7289126.
Vekemans MC, Lambert C, Ferrant A, Saussoy P, Havelange V, Debiève F, et al
. Management of pregnancy in paroxysmal nocturnal hemoglobinuria on long-term eculizumab. Blood Coagul Fibrinolysis 2015;26:464-6.
Gessoni G, Canistro R, Bergamini L, Valverde S, Gessoni F, Nani G, et al
. Postpartum thrombotic complication in a patient with paroxysmal nocturnal hemoglobinuria. Blood Coagul Fibrinolysis 2015;26:458-63.
Bais J, Pel M, von dem Borne A, van der Lelie H. Pregnancy and paroxysmal nocturnal hemoglobinuria. Eur J Obstet Gynecol Reprod Biol 1994;53:211-4.
Sasano T, Tomimatsu T, Nishimura J, Matsumura I, Kanakura Y, Kimura T. Two consecutive pregnancies in a patient with paroxysmal nocturnal haemoglobinuria treated with anticoagulant therapy at different doses. Blood Coagul Fibrinolysis 2016;27:109-12.
Moyo VM, Mukhina GL, Garrett ES, Brodsky RA. Natural history of paroxysmal nocturnal haemoglobinuria using modern diagnostic assays. Br J Haematol 2004;126:133-8.
Morita Y, Nishimura J, Shimada T, Tanaka H, Serizawa K, Taniguchi Y, et al
. Successful anticoagulant therapy for two pregnant PNH patients, and prospects for the eculizumab era. Int J Hematol 2013;97:491-7.
Kelly R, Arnold L, Richards S, Hill A, Bomken C, Hanley J, et al
. The management of pregnancy in paroxysmal nocturnal haemoglobinuria on long term eculizumab. Br J Haematol 2010;149:446-50.
Sarno L, Tufano A, Maruotti GM, Martinelli P, Balletta MM, Russo D. Eculizumab in pregnancy: A narrative overview. J Nephrol 2019;32:17-25.
[Table 1], [Table 2], [Table 3], [Table 4]